Literature DB >> 22670775

Oral treatment with Hev b 13 ameliorates experimental colitis in mice.

L B Teixeira1, V L A A Epifânio, J J Lachat, N T Foss, J Coutinho-Netto.   

Abstract

Hev b 13 is an allergenic esterase obtained from the rubber tree Hevea brasiliensis, which has been shown recently to induce human mononuclear cells to release interleukin (IL)-10 in vitro. This immunoregulatory cytokine appears to play an important role in preventing inflammation and mucosal damage in animal models of colitis and in Crohn's disease patients. The aim of this study was to evaluate the therapeutic effect of Hev b 13 in mice with 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis. Two hours following colonic instillation of the haptenizing agent, and daily thereafter for 5 days, Hev b 13 was administered by oral gavage. In mice treated with daily doses of either 0·5 mg/kg or 5·0 mg/kg of Hev b 13, the clinical signs of diarrhoea, rectal prolapse and body weight loss and also histological damage of the distal colon, were reduced significantly, in comparison with water-treated diseased mice. These findings suggest a potent anti-inflammatory activity of Hev b 13; this activity is speculated to be related to its interaction with cells from the immune system.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22670775      PMCID: PMC3390470          DOI: 10.1111/j.1365-2249.2012.04589.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

Review 1.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

Review 2.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

3.  Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers.

Authors:  H H Herfarth; S P Mohanty; H C Rath; S Tonkonogy; R B Sartor
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

4.  Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

Authors:  I J Fuss; T Marth; M F Neurath; G R Pearlstein; A Jain; W Strober
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

Review 5.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

6.  Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease.

Authors:  B Meresse; P Rutgeerts; H Malchow; S Dubucquoi; J P Dessaint; M Cohard; J F Colombel; P Desreumaux
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

7.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

8.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.

Authors:  S J van Deventer; C O Elson; R N Fedorak
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

9.  Latex allergy: low prevalence of immunoglobulin E to highly purified proteins Hev b 2 and Hev b 13.

Authors:  T Palosuo; M Lehto; A Kotovuori; N Kalkkinen; C Blanco; P Poza; T Carrillo; R G Hamilton; H Alenius; T Reunala; K Turjanmaa
Journal:  Clin Exp Allergy       Date:  2007-09-10       Impact factor: 5.018

10.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

View more
  3 in total

1.  Oral treatment with Hev b 13 prevents experimental arthritis in mice.

Authors:  Larissa De Bortoli Teixeira; Vera Lúcia Aparecida Aguillar Epifânio; João José Lachat; Norma Tiraboschi Foss; Joaquim Coutinho-Netto
Journal:  Clin Exp Immunol       Date:  2012-06       Impact factor: 4.330

2.  Anticolitis activity of Chinese herbal formula yupingfeng powder via regulating colonic enterochromaffin cells and serotonin.

Authors:  Kai-hong Zang; Zhi Rao; Guo-qiang Zhang; Hong-yan Qin
Journal:  Indian J Pharmacol       Date:  2015 Nov-Dec       Impact factor: 1.200

3.  IMMUNOMODULATING EFFECTS OF THE PURIFIED HEV B 13 FRACTION ON SEPTIC RATS.

Authors:  Maxley Martins Alves; Lilhian Alves de Araújo; Fátima Mrué; Clayson Moura Gomes; Milton Adriano Pelli de Oliveira; Roberpaulo Anacleto Neves; Nelson Jorge da Silva-Júnior; Paulo Roberto de Melo-Reis
Journal:  Arq Bras Cir Dig       Date:  2017 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.